Acamprosate CA EC 333mg Tablet Manufacturing

The contract involves the full-scale manufacturing of Acamprosate Calcium Enteric Coated Tablets, each containing 333mg of the active ingredient, in compliance with FDA current Good Manufacturing Practice (cGMP) standards. The scope of work includes formulation development, tablet coating, rigorous quality control testing, and the timely release of production batches. The production process must meet stringent regulatory requirements to ensure product safety and efficacy. This subcontract is issued by Nac Pharmaceuticals, operating under the Department of Veterans Affairs, with the solicitation posted on May 14, 2026. Interested parties must submit their responses by May 28, 2026. The contract falls under NAICS code 325412, which pertains to pharmaceutical preparation manufacturing. Specific details about the place of performance and points of contact are not provided, but the work is expected to adhere strictly to all regulatory and quality standards set forth by the FDA and the contracting agency.